T88.3 Malignant hyperthermia due to anesthesia

Name of the Condition

• Malignant hyperthermia due to anesthesia
• ICD-10 Code: T88.3

Summary

Malignant hyperthermia is a rare, life-threatening reaction triggered by certain anesthetic agents. It involves a rapid increase in body temperature and severe muscle rigidity, requiring immediate medical intervention. This condition is classified under complications of anesthesia and is not associated with other causes of hyperthermia.

Causes

The reaction is typically triggered by volatile anesthetic gases (e.g., sevoflurane, desflurane) or succinylcholine, a muscle relaxant. It results from a genetic predisposition affecting calcium regulation in muscle cells, leading to uncontrolled muscle contraction and heat production.

Risk Factors

• Genetic susceptibility (often inherited)
• Prior personal or family history of malignant hyperthermia
• Exposure to triggering anesthetics in susceptible individuals

Symptoms

• Rapid rise in body temperature (hyperthermia)
• Severe muscle stiffness or rigidity
• Rapid heart rate (tachycardia)
• Rapid breathing (tachypnea)
• Muscle breakdown (rhabdomyolysis)
• Dark urine (myoglobinuria)
• Acidosis or electrolyte imbalances

Diagnosis

Diagnosis is based on clinical presentation during or after anesthesia, including unexplained hyperthermia and muscle rigidity. Confirmation may involve muscle biopsy for caffeine-halothane contracture testing or genetic testing for known mutations. Laboratory tests may show elevated creatine kinase (CK) and myoglobin levels.

Treatment Options

• Immediate discontinuation of triggering anesthetics
• Administration of dantrolene, a muscle relaxant that reverses the reaction
• Aggressive cooling measures (e.g., ice packs, cooling blankets)
• Supportive care for organ function (e.g., hydration, electrolyte correction)
• Monitoring for complications like kidney failure or cardiac arrhythmias

Prognosis and Follow-Up

With prompt treatment, prognosis is generally good, but delays can lead to severe complications or death. Survivors require follow-up to assess organ function and avoid future exposure to triggering agents. Genetic counseling may be recommended for affected individuals and their families.

Complications

• Kidney failure due to muscle breakdown
• Cardiac arrhythmias or heart failure
• Neurological damage from prolonged hyperthermia
• Death (in severe, untreated cases)

Lifestyle & Prevention

• Avoidance of triggering anesthetics in susceptible individuals
• Use of alternative anesthetics (e.g., regional anesthesia) when possible
• Preoperative screening for genetic risk factors
• Carrying a medical alert bracelet or document indicating susceptibility

When to Seek Professional Help

Seek immediate medical attention if hyperthermia, muscle rigidity, or other symptoms occur during or after anesthesia. Early recognition and treatment are critical to prevent life-threatening complications.

Tips for Medical Coders

Document the triggering anesthetic agent, clinical signs (e.g., hyperthermia, muscle rigidity), and treatment (e.g., dantrolene administration). Ensure the code is used only for anesthesia-related malignant hyperthermia, not for other causes of hyperthermia. Include details of genetic testing or family history if available to support the diagnosis.